Abstract:S9.3 Drug resistance in emerging pathogenic fungi, September 23, 2022, 4:45 PM - 6:15 PM Candida albicans is an opportunistic fungal pathogen. While nearly 40%-60% of humans are colonized harmlessly by C. albicans , prolonged use of antibiotics or an immune-compromised status can lead to mucosal or deadly systemic candidiasis (Kumamoto et al., 2020). There are only three classes of antifungals available to physicians to treat and prevent severe Candidiasis. These drugs, which include polyenes, echinocandins, and azoles, protect the host by killing or inhibiting growth of C. albicans , thereby exerting a strong selective pressure toward drug resistance.Antivirulence drugs, by contrast, target virulence traits of pathogens without affecting their growth, making drug resistance less likely to evolve. We seek to discover novel antivirulence compounds against C. albicans that keep it at, or return it to, its baseline commensal state even under conditions that support pathogenicity.Bacteria have evolved a large repository of metabolites that can inhibit and modulate the behavior of other organisms in their environment. Clades like the predatory myxobacteria are untapped for potential antifungal and antivirulence drug discovery (Vij et al., 2021). We here screened ≈ 2800 crude extracts from myxobacteria in an in situ C. albicans -mammalian epithelial cell infection model. Typically, when oral epithelial cells (TR146) are infected by C. albicans , the fungus proliferates, forms hyphae, and invades and damages the monolayer. In our assay, we estimate the damage to epithelial cells by released lactate dehydrogenase. We also note changes to the growth and morphology of the fungus. Based on these readouts we assign antivirulence and antifungal ranks to each extract, and confirm top-ranked hits with an independent propidium iodide-based assay for host cell damage, and a colorimetric assay of fungal metabolic activity. We found that several of the top-ranked antifungal extracts also showed effects on a multi-drug resistant strain of C. auris .Using an established pipeline, we identified several of the antifungal and antivirulent bioactive components in these extracts. After scaling the production of promising lead compounds, we will test their drugability on clinical Candida spp. strains, and identify their mode of action using large-scale Candida spp. knock-out libraries and multi-omics approaches.Our tested extracts are likely to contain new classes of non-toxic antifungals that can potentially treat infections by multi-drug resistant fungi. We identified and confirmed several myxobacteria extracts that protected mammalian epithelial cells without severely affecting the fungus' growth, which are, therefore, considered antivirulent.Sources: Kumamoto, C. A., Gresnigt, M.S., Hube, B., 2020. The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. Curr. Opin. Microbiol. 56, 7–15. https://doi.org/10.1016/j.mib.2020.05.006 Vij, R., Hube, B., Brunke, S., 2021. Uncharted territories in the discovery of antifungal and antivirulence natural products from bacteria. Comput. Struct. Biotechnol. J. 19, 1244–1252. https://doi.org/10.1016/j.csbj.2021.02.003

Optimization of the antifungal properties of the bacterial peptide EntV by variant analysis

Use of Haploid Model of Candida Albicans to Uncover Mechanism of Action of a Novel Antifungal Agent.

Short peptides derived from EntV inhibit virulence and biofilm formation in Candida albicans

Hydrophobic diversification is the key to simultaneously increased antifungal activity and decreased cytotoxicity of two ab initio designed peptides

Machine Learning-Driven Discovery of Highly Selective Antifungal Peptides Containing Non-Canonical β-Amino Acids

Symbiotic NCR Peptide Fragments Affect the Viability, Morphology and Biofilm Formation of Candida Species

Optimizing therapeutic efficacy of antifungal peptides via strategic terminal amino acid modification

A Novel Dual-Targeted Α-Helical Peptide with Potent Antifungal Activity Against Fluconazole-Resistant Candida Albicans Clinical Isolates.

Anti-fungal peptides: an emerging category with enthralling therapeutic prospects in the treatment of candidiasis

Biochemical Characterization of Recombinant Enterococcus faecalis EntV Peptide to Elucidate Its Antihyphal and Antifungal Mechanisms against Candida albicans

Rational design, synthesis, antifungal evaluation and docking studies of antifungal peptide CGA-N12 analogues based on the target CtKRE9

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Antifungal activity of a de novo synthetic peptide and derivatives against fungal food contaminants

Anticandidal activity of synthetic peptides: Mechanism of action revealed by scanning electron and fluorescence microscopies and synergism effect with nystatin

A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida Albicans Vaginitis

Regulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics

Efficacy of two novel antifungal lipopeptides, AF4 and AF5 of bacillomycin D family in murine models of invasive candidiasis, cryptococcosis, and aspergillosis

Anti-Infective Antibody-Derived Peptides Active against Endogenous and Exogenous Fungi

S9.3d Antivirulence drug discovery to disarm Candida albicans with metabolites from myxobacteria.

Two promising natural lipopeptides from Bacillus subtilis effectively induced membrane permeabilization in Candida glabrata

Biomimetic Antifungal Materials: Countering the Challenge of Multidrug-Resistant Fungi